| 000 | 00823 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250517105727.0 | ||
| 264 | 0 | _c20180305 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(16)30220-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGisselbrecht, Christian | |
| 245 | 0 | 0 |
_aIs nivolumab an option for Hodgkin's lymphoma? _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _c09 2016 |
||
| 300 |
_a1183-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal |
| 650 | 0 | 4 | _aHodgkin Disease |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aNivolumab |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 17 _gno. 9 _gp. 1183-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(16)30220-0 _zAvailable from publisher's website |
| 999 |
_c26259321 _d26259321 |
||